Altitude Life Science Ventures
Kirkland, Washington, United StatesFounded 2006
Altitude Life Science Ventures specializes in investing in early-stage life science companies, focusing on biotechnology, drug discovery, therapeutic devices, and digital health. The firm's strategy involves backing high-potential startups that address significant market needs with innovative solutions, often emphasizing intellectual property strategic planning and extended due diligence.
100% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $137.9M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Lila Sciences | Seed | $200M | Mar 2025 |
 Vilya, Inc. | Series A | $71M | Jun 2024 |
 Mozart Therapeutics, Inc. | Series A | $55M | Oct 2021 |
 Omniome, Inc. | Series C | $60M | Jan 2020 |
 Encoded Therapeutics, Inc. | Series C | $104M | Jun 2019 |
 eFFECTOR Therapeutics | Series B | $40M | Dec 2015 |
| SSana Biotechnology | Growth | $435M | — |
Top Co-Investors
ARCH Venture Partners5 shared
Alexandria Venture Investments2 shared
Flagship Pioneering2 shared
Menlo Ventures2 shared
Sofinnova Partners1 shared
MRL Ventures Fund1 shared
Leaps by Bayer1 shared
Baillie Gifford1 shared
F-Prime Capital1 shared
Alaska Permanent Fund1 shared
Bezos Expeditions1 shared
GV (Google Ventures)1 shared
Omega Funds1 shared
Matrix Partners1 shared
Venrock1 shared
Illumina Ventures1 shared
RTW Investments1 shared
Boxer Capital of the Tavistock Group1 shared
Domain Associates1 shared
Last updated: 8 March 2026